Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.
Effectiveness and Durability of COVID-19 Vaccination in 9447 Patients With IBD: A Systematic Review and Meta-Analysis.
复制标题
DOI：
10.1016/j.cgh.2022.02.030
复制
发表时间：
2022-07
期刊：
影响因子：
--
通讯作者：
Sharma V
中科院分区：
文献类型：
--
作者：
Jena A;James D;Singh AK;Dutta U;Sebastian S;Sharma V
在免疫功能低下的个体中，接种严重急性呼吸综合征冠状病毒2型疫苗后的血清学应答可能减弱。该研究旨在系统评估炎症性肠病（IBD）患者完全接种2019冠状病毒病（COVID-19）疫苗后的血清转换率。检索了电子数据库，以确定报告IBD中COVID-19疫苗接种反应的研究。计算完全接种后的合并血清转化率。还进行了疫苗类型的亚组分析。还估计了各种药物或类别的合并血清转化率。估计了接种IBD疫苗患者的合并突破性感染率。还估计了完全疫苗接种后的合并中和率。对报告滴度持久性的研究进行了系统评估。共纳入46项研究。完全疫苗接种（31项研究，9447例患者）的合并血清转化率为0.96（95%置信区间[CI]，0.94-0.97; I2 = 90%）。与健康对照受试者相比，血清转换的合并相对风险较低（0.98; 95% CI，0.98-0.99; I2 = 39%）。各种药物类别之间的合并血清转化率在统计学上相似。中和试验（8项研究，771例受试者）的合并阳性率为0.80（95% CI，0.70-0.87; I2 = 82%）。IBD疫苗接种患者中突破性感染的合并相对风险与接种对照受试者相似（0.60; 95% CI，0.25-1.42; I2 = 79%）。大多数研究表明，接种COVID-19疫苗4周后，滴度下降，并且在单独使用抗肿瘤坏死因子或与免疫调节剂联合使用的患者中衰减更高。额外剂量的COVID-19疫苗在大多数无应答者中引发了血清学应答，以完成疫苗接种。在大多数IBD患者中，完全COVID-19疫苗接种与血清转化相关。滴度随时间的衰减需要考虑在这些患者中使用额外剂量。
The serological responses after severe acute respiratory syndrome coronavirus 2 vaccination may be attenuated in immunocompromised individuals. The study aimed to systematically evaluate the seroconversion rates after complete vaccination for coronavirus disease 2019 (COVID-19) in patients with inflammatory bowel disease (IBD). Electronic databases were searched to identify studies reporting response to COVID-19 vaccination in IBD. Pooled seroconversion rates after complete vaccination were calculated. Subgroup analysis for vaccine types was also performed. Pooled seroconversion rates for various drugs or classes were also estimated. The pooled rates of breakthrough infections in vaccinated IBD patients were estimated. The pooled neutralization rates after complete vaccination were also estimated. The studies reporting durability of titers were systematically assessed. A total of 46 studies were included. The pooled seroconversion rate for complete vaccination (31 studies, 9447 patients) was 0.96 (95% confidence interval [CI], 0.94–0.97; I2 = 90%). When compared with healthy control subjects, the pooled relative risk of seroconversion was lower (0.98; 95% CI, 0.98–0.99; I2 = 39%). The pooled seroconversion rates were statistically similar among various drug classes. The pooled positivity of neutralization assays (8 studies, 771 participants) was 0.80 (95% CI, 0.70–0.87; I2 = 82%). The pooled relative risk of breakthrough infections in vaccinated IBD patients was similar to vaccinated control subjects (0.60; 95% CI, 0.25–1.42; I2 = 79%). Most studies suggested that titers fall after 4 weeks of COVID-19 vaccination, and the decay was higher in patients on anti-tumor necrosis factor alone or combination with immunomodulators. An additional dose of COVID-19 vaccine elicited serological response in most nonresponders to complete vaccination. Complete COVID-19 vaccination is associated with seroconversion in most patients with IBD. The decay in titers over time necessitates consideration of additional doses in these patients.
登录
查看更多内容
DOI：
10.1016/j.medj.2021.11.004
发表时间：
2021-12-10
期刊：
Med (New York, N.Y.)
影响因子：
--
作者：
Chen RE;Gorman MJ;Zhu DY;Carreño JM;Yuan D;VanBlargan LA;Burdess S;Lauffenburger DA;Kim W;Turner JS;Droit L;Handley SA;Chahin S;Deepak P;O'Halloran JA;Paley MA;Presti RM;Wu GF;Krammer F;Alter G;Ellebedy AH;Kim AHJ;Diamond MS
通讯作者：
Diamond MS
CoVID-19疫苗或感染引起的SARS-COV-2 T细胞反应预计将保持对Omicron的稳健性。
DOI：
10.3390/v14010079
发表时间：
2022-01-02
期刊：
Viruses
影响因子：
--
作者：
Ahmed SF;Quadeer AA;McKay MR
通讯作者：
McKay MR
影响因子：
2.3
作者：
Classen, Johanna Maria;Muzalyova, Anna;Schnoy, Elisabeth
通讯作者：
Schnoy, Elisabeth
影响因子：
9.8
作者：
Caldera, Freddy;Knutson, Keith L.;Farraye, Francis A.
通讯作者：
Farraye, Francis A.
影响因子：
13.6
作者：
Jena A;Mishra S;Deepak P;Kumar-M P;Sharma A;Patel YI;Kennedy NA;Kim AHJ;Sharma V;Sebastian S
通讯作者：
Sebastian S